About us
Welcome to the Nordic collaboration JNHB
The Nordic collaboration JNHB offers efficient and transparent joint health technology assessments of medicinal products in the five Nordic countries.
NEWS
January 13 2025
- The Joint Nordic HTA-Bodies are well prepared for work under the EU HTA regulation
Ongoing assessments
- Ivosidenib (Tibsovo) in combination with azacitidine is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) with an isocitrate dehydrogenase-1 (IDH1) R132 mutation who are not eligible to receive standard induction chemotherapy.
- Omaveloxolone (Skyclarys) for the treatment of Friedreich’s ataxia in adults and adolescents aged 16 years and older.
- Tofersen (Qalsody) for the treatment of adults with amyotrophic lateral sclerosis (ALS), associated with a mutation in the superoxide dismutase 1 (SOD1) gene
All relevant documents regarding joint Nordic assessments
Process guideline:
Submission dossier template:
Q&A:
Waiver of confidentiality:
Memorandum of understanding:
JNHB - NED collaboration: